Wolff Wiese Magana’s CRISPR Therapeutics CRSP Stock Holding History

Wolff Wiese Magana’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.45K	Hold	100	–	–	﹤0.01%	624
2026 Q1	$4.76K	Hold	100	–	–	﹤0.01%	616
2025 Q4	$5.24K	Hold	100	–	–	﹤0.01%	571
2025 Q3	$6.48K	Hold	100	–	–	﹤0.01%	543
2025 Q2	$4.86K	Hold	100	–	–	﹤0.01%	567
2025 Q1	$3.4K	Hold	100	–	–	﹤0.01%	645
2024 Q4	$3.94K	Hold	100	–	–	﹤0.01%	597
2024 Q3	$4.7K	Hold	100	–	–	﹤0.01%	587
2024 Q2	$5.4K	Hold	100	–	–	﹤0.01%	415
2024 Q1	$6.82K	Hold	100	–	–	0.01%	347
2023 Q4	$6.26K	Hold	100	–	–	0.01%	349
2023 Q3	$4.54K	Hold	100	–	–	﹤0.01%	447
2023 Q2	$5.61K	Hold	100	–	–	﹤0.01%	429
2023 Q1	$4.52K	Sell	100 -28	-22%	-$1.36K	﹤0.01%	438
2022 Q4	$5.2K	Hold	128	–	–	﹤0.01%	407
2022 Q3	$8K	Hold	128	–	–	0.01%	528
2022 Q2	$8K	Buy	128 +3	+2%	+$176	0.01%	561
2022 Q1	$8K	Hold	125	–	–	0.01%	564
2021 Q4	$9K	Hold	125	–	–	0.01%	562
2021 Q3	$14K	Hold	125	–	–	0.01%	472
2021 Q2	$20K	Hold	125	–	–	0.01%	396
2021 Q1	$15K	Sell	125 -1,174	-90%	-$177K	0.01%	424
2020 Q4	$199K	Buy	+1,299	New	+$154K	0.17%	109

Other funds holding CRSP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Wolff Wiese Magana's CRSP Position: Q2 2026 in Review

Wolff Wiese Magana held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 100 shares worth $5.45K. The position accounts for ﹤0.01% of the portfolio, ranked #624.

Wolff Wiese Magana first reported a position in CRSP in Q4 2020 and has held it in 23 quarters since. The position peaked at $199K in Q4 2020. 252 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Wolff Wiese Magana held 100 shares of CRISPR Therapeutics worth $5.45K as of Q2 2026.
Wolff Wiese Magana left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of Wolff Wiese Magana's portfolio in Q2 2026, its #624 holding.
Wolff Wiese Magana first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 23 quarters since.
Wolff Wiese Magana's CRISPR Therapeutics position peaked at $199K in Q4 2020.
252 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Wolff Wiese Magana's 13F filing for Q2 2026, filed 13 Jul 2026.